BURLINGAME, Calif., July 30, 2015 /PRNewswire/ -- Cleave Biosciences today announced that the United States Patent and Trademark Office has granted the company a key patent providing the protection of intellectual property covering Cleave's lead molecule CB-5083.
This newly issued patent, "Fused pyrimidines and substituted quinazolines as inhibitors of p97," U.S. 9,062,026, allows for claims on the composition of matter of CB-5083, a first-in-class, highly selective oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. Cleave is currently evaluating CB-5083 as an anti-cancer agent in two Phase 1 studies, one in patients with multiple myeloma and one in patients with solid tumors.
"This patent is a clear demonstration of the innovative nature of CB-5083 and builds the value of our proprietary compound," said Laura Shawver, Ph.D., chief executive officer of Cleave Biosciences.
About Cleave Biosciences
Biopharmaceutical company Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems and have the potential to transform the treatment of people with difficult to treat solid tumors and hematologic malignancies. The company is privately held and located in Burlingame, California. For additional information, visit www.cleavebio.com.
Laura Shawver, Ph.D.
Chief Executive Officer
Senior Vice President
SOURCE Cleave Biosciences